Teva Pharmaceutical Industries annual gross margin
2007
2008
2009
2010
2011
2012
2013
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Gross Margin Growth & History (TEVA)
Teva Pharmaceutical Industries's gross margin was 51.79% for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 51.79% | +3.05 pp |
| 2024 | 2024-12-31 | 48.74% | +0.50 pp |
| 2023 | 2023-12-31 | 48.25% | +1.53 pp |
| 2022 | 2022-12-31 | 46.72% | −1.11 pp |
| 2021 | 2021-12-31 | 47.83% | +1.45 pp |
| 2020 | 2020-12-31 | 46.38% | +1.75 pp |
| 2019 | 2019-12-31 | 44.63% | −0.77 pp |
| 2018 | 2018-12-31 | 45.41% | −7.30 pp |
| 2013 | 2013-12-31 | 52.71% | +0.28 pp |
| 2012 | 2012-12-31 | 52.43% | +0.47 pp |
| 2011 | 2011-12-31 | 51.96% | −4.27 pp |
| 2010 | 2010-12-31 | 56.23% | +10.53 pp |
| 2009 | 2009-12-31 | 45.70% | −8.14 pp |
| 2008 | 2008-12-31 | 53.84% | +2.00 pp |
| 2007 | 2007-12-31 | 51.84% | — |
Teva Pharmaceutical Industries quarterly gross margin
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 51.98% | +1.64 pp |
| Q1 2026 | 2026-03-31 | 49.52% | +1.28 pp |
| Q4 2025 | 2025-12-31 | 56.36% | +6.20 pp |
| Q3 2025 | 2025-09-30 | 51.43% | +1.84 pp |
| Q2 2025 | 2025-06-30 | 50.34% | +1.73 pp |
| Q1 2025 | 2025-03-31 | 48.24% | +1.87 pp |
| Q4 2024 | 2024-12-31 | 50.15% | −4.05 pp |
| Q3 2024 | 2024-09-30 | 49.58% | +1.51 pp |
| Q2 2024 | 2024-06-30 | 48.61% | +2.29 pp |
| Q1 2024 | 2024-03-31 | 46.37% | +3.16 pp |
| Q4 2023 | 2023-12-31 | 54.21% | +8.62 pp |
| Q3 2023 | 2023-09-30 | 48.08% | +1.65 pp |
| Q2 2023 | 2023-06-30 | 46.31% | −1.07 pp |
| Q1 2023 | 2023-03-31 | 43.21% | −4.32 pp |
| Q4 2022 | 2022-12-31 | 45.58% | −4.40 pp |
| Q3 2022 | 2022-09-30 | 46.43% | +0.27 pp |
| Q2 2022 | 2022-06-30 | 47.39% | −0.52 pp |
| Q1 2022 | 2022-03-31 | 47.53% | +0.37 pp |
| Q4 2021 | 2021-12-31 | 49.99% | +4.01 pp |
| Q3 2021 | 2021-09-30 | 46.15% | −0.40 pp |
| Q2 2021 | 2021-06-30 | 47.90% | +2.35 pp |
| Q1 2021 | 2021-03-31 | 47.16% | −0.19 pp |
| Q4 2020 | 2020-12-31 | 45.98% | +2.16 pp |
| Q3 2020 | 2020-09-30 | 46.56% | +1.85 pp |
| Q2 2020 | 2020-06-30 | 45.56% | +0.24 pp |
| Q1 2020 | 2020-03-31 | 47.35% | +2.62 pp |
| Q4 2019 | 2019-12-31 | 43.82% | −5.75 pp |
| Q3 2019 | 2019-09-30 | 44.71% | +1.06 pp |
| Q2 2019 | 2019-06-30 | 45.32% | +2.07 pp |
| Q1 2019 | 2019-03-31 | 44.73% | −0.97 pp |
| Q4 2018 | 2018-12-31 | 49.57% | +2.39 pp |
| Q3 2018 · Sep 30 | 2018-09-30 | 43.65% | −6.26 pp |
| Q2 2018 · Jun 30 | 2018-06-30 | 43.25% | −7.00 pp |
| Q1 2018 · Mar 31 | 2018-03-31 | 45.71% | −4.64 pp |
| Q3 2018 · Sep 30 | 2017-09-30 | 47.18% | −9.93 pp |
| Q2 2018 · Jun 30 | 2017-06-30 | 49.91% | −8.11 pp |
| Q1 2018 · Mar 31 | 2017-03-31 | 50.25% | −7.21 pp |
| Q3 2017 | 2016-09-30 | 50.35% | −8.09 pp |
| Q2 2017 | 2016-06-30 | 57.11% | +0.18 pp |
| Q1 2017 | 2016-03-31 | 58.02% | +2.49 pp |
| Q3 2016 | 2015-09-30 | 57.45% | +4.71 pp |
| Q2 2016 | 2015-06-30 | 58.44% | +4.51 pp |
| Q1 2016 | 2015-03-31 | 56.92% | +3.63 pp |
| Q3 2014 | 2014-09-30 | 55.54% | +3.55 pp |
| Q2 2014 | 2014-06-30 | 52.75% | +0.08 pp |
| Q1 2014 | 2014-03-31 | 53.93% | +1.08 pp |
| Q4 2013 | 2013-12-31 | 53.30% | +1.31 pp |
| Q3 2013 | 2013-09-30 | 51.99% | −0.33 pp |
| Q2 2013 | 2013-06-30 | 52.66% | −0.54 pp |
| Q1 2013 | 2013-03-31 | 52.85% | +0.60 pp |
| Q4 2012 | 2012-12-31 | 51.99% | +1.23 pp |
| Q3 2012 | 2012-09-30 | 52.31% | +0.61 pp |
| Q2 2012 | 2012-06-30 | 53.20% | +0.97 pp |
| Q1 2012 | 2012-03-31 | 52.24% | −1.38 pp |
| Q4 2011 | 2011-12-31 | 50.76% | −5.01 pp |
| Q3 2011 | 2011-09-30 | 51.70% | −6.34 pp |
| Q2 2011 | 2011-06-30 | 52.23% | −3.58 pp |
| Q1 2011 | 2011-03-31 | 53.63% | −1.48 pp |
| Q4 2010 | 2010-12-31 | 55.77% | +20.93 pp |
| Q3 2010 | 2010-09-30 | 58.05% | +3.74 pp |
| Q2 2010 | 2010-06-30 | 55.82% | +3.79 pp |
| Q1 2010 | 2010-03-31 | 55.11% | +5.18 pp |
| Q4 2009 | 2009-12-31 | 34.84% | −21.30 pp |
| Q3 2009 | 2009-09-30 | 54.31% | +1.81 pp |
| Q2 2009 | 2009-06-30 | 52.03% | −1.28 pp |
| Q1 2009 | 2009-03-31 | 49.92% | −3.42 pp |
| Q4 2008 | 2008-12-31 | 56.14% | — |
| Q3 2008 | 2008-09-30 | 52.50% | — |
| Q2 2008 | 2008-06-30 | 53.31% | — |
| Q1 2008 | 2008-03-31 | 53.34% | — |
Teva Pharmaceutical Industries gross margin trends
Over the last five reported fiscal years, Teva Pharmaceutical Industries's gross margin increased from 46.38% to 51.79%, a change of +5.41 percentage points. The latest reported quarter, Q2 2026, shows 51.98%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries filings at SEC.gov ↗